(Q48075810)

8 February 2018

title

Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients (English)

1 reference

8 February 2018

0 references

1 reference

Marta Garcia-Montojo

1

1 reference

8 February 2018

Virginia De Las Heras

2

1 reference

8 February 2018

Manuel Bartolome

3

1 reference

8 February 2018

Rafael Arroyo

4

1 reference

8 February 2018

Roberto Alvarez-Lafuente

5

1 reference

8 February 2018

publication date

1 December 2007

1 reference

8 February 2018

published in

Journal of NeuroVirology

1 reference

8 February 2018

volume

13

1 reference

8 February 2018

issue

6

1 reference

8 February 2018

page(s)

504-512

1 reference

8 February 2018

https://scigraph.springernature.com/pub.10.1080/13550280701649670

exact match

0 references

cites work

Prevalence of herpesvirus DNA in MS patients and healthy blood donors

1 reference

12 December 2020

Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis

1 reference

12 December 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

12 December 2020

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

1 reference

12 December 2020

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

1 reference

12 December 2020

Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes

1 reference

12 December 2020

T-lymphocyte entry into the central nervous system

1 reference

12 December 2020

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

12 December 2020

Active human herpesvirus 6 infection in patients with multiple sclerosis

1 reference

12 December 2020

Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.

1 reference

12 December 2020

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

1 reference

12 December 2020

Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm

1 reference

12 December 2020

Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination

1 reference

12 December 2020

High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection.

1 reference

12 December 2020

Correlation between HHV-6 reactivation and multiple sclerosis disease activity.

1 reference

12 December 2020

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

1 reference

12 December 2020

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

12 December 2020

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

1 reference

12 December 2020

Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater.

1 reference

12 December 2020

Gelatinase B functions as regulator and effector in leukocyte biology

1 reference

12 December 2020

Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

1 reference

12 December 2020

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis

1 reference

12 December 2020

Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Matrix metalloproteinases and diseases of the CNS.

1 reference

12 December 2020

Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B.

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

10.1080/13550280701649670

Identifiers

DOI

1 reference

8 February 2018

Dimensions Publication ID

1020343715

0 references

1 reference

8 February 2018